{
    "body": "What is the mechanism of action of solanezumab?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24101429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21784350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23568994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21868184", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24353405", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24063020", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22482074", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21504387", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22848160", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24259408", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22506132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23582316", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23847530", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22110351", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21694458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23254906", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23574434", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22288451", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21897718", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22134132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22672770", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23416764", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23735288", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22339463", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22292124", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23663286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20375655", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21614635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24119446", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24399967"
    ], 
    "triples": [
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_type", 
            "s": "http://data.linkedct.org/resource/intervention/13258", 
            "o": "Drug"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_name", 
            "s": "http://data.linkedct.org/resource/intervention/13258", 
            "o": "Solanezumab"
        }, 
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://data.linkedct.org/resource/intervention/13258", 
            "o": "Intervention #13258 (Drug:Solanezumab)"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#broader", 
            "s": "http://linkedlifedata.com/resource/umls/id/C2935150", 
            "o": "http://linkedlifedata.com/resource/umls/id/C0003250"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A18469068", 
            "o": "solanezumab"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A17949023", 
            "o": "Antibodies, Monoclonal [Chemical/Ingredient]"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0024758", 
            "o": "Antibodies, Monoclonal"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A7654540", 
            "o": "Monoclonal Antibody"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A4346004", 
            "o": "monoclonal antibodies"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A7572230", 
            "o": "Monoclonal Antibodies"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A10786467", 
            "o": "MoAB"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C2935150", 
            "o": "http://linkedlifedata.com/resource/umls/label/A18469068"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A1307845", 
            "o": "MAb"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0319457", 
            "o": "monoclonal antibody"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#notation", 
            "s": "http://linkedlifedata.com/resource/umls/label/A18469068", 
            "o": "C550616"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#note", 
            "s": "http://linkedlifedata.com/resource/umls/label/A18469068", 
            "o": "MeSH"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#broader", 
            "s": "http://linkedlifedata.com/resource/umls/id/C2935151", 
            "o": "http://linkedlifedata.com/resource/umls/id/C2935150"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A18472154", 
            "o": "LY-2062430"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A18456783", 
            "o": "LY 2062430"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A18465965", 
            "o": "LY2062430"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention", 
            "s": "http://data.linkedct.org/resource/trials/NCT00637130", 
            "o": "http://data.linkedct.org/resource/intervention/13258"
        }, 
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://data.linkedct.org/resource/trials/NCT00637130", 
            "o": "Trial NCT00637130"
        }, 
        {
            "p": "http://data.linkedct.org/resource/linkedct/intervention_id", 
            "s": "http://data.linkedct.org/resource/intervention/13258", 
            "o": "13258"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#narrower", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0003250", 
            "o": "http://linkedlifedata.com/resource/umls/id/C2935150"
        }
    ], 
    "ideal_answer": [
        "Solanezumab is a monoclonal anti-amyloid beta peptide (A\u03b2) antibody. It has been tested for treatment of Alzheimer's disease patients.", 
        "Solanezumab, a humanized anti-A\u03b2 monoclonal antibody directed against the midregion of the A\u03b2 peptide, was shown to neutralize soluble A\u03b2 species."
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"
    ], 
    "type": "summary", 
    "id": "52fc94ae2059c6d71c000073", 
    "snippets": [
        {
            "offsetInBeginSection": 1156, 
            "offsetInEndSection": 1456, 
            "text": "Anti-amyloid treatment in asymptomatic AD (A4) is a prevention trial aimed at treating older individuals with normal cognition but at risk of developing AD dementia on the basis of having biomarker evidence of amyloid (preclinical AD). They selected solanezumab for the anti-amyloid treatment for A4.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24101429", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 830, 
            "offsetInEndSection": 1056, 
            "text": "Passive immunotherapy with monoclonal antibodies (mAbs) against A\u03b2 is in late clinical development but recently the two most advanced mAbs, Bapineuzumab and Solanezumab, targeting an N-terminal or central epitope, respectively", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23663286", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 354, 
            "offsetInEndSection": 389, 
            "text": "solanezumab, targeting monomeric A\u03b2", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582316", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 136, 
            "offsetInEndSection": 387, 
            "text": "Immunotherapeutic agents have been developed to remove the neurotoxic amyloid \u03b242 protein and prevent the hypothesized amyloid \u03b242-induced neurotoxicity and neurodegeneration. The most notable of these immunotherapies are bapineuzumab and solanezumab.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23574434", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 742, 
            "offsetInEndSection": 891, 
            "text": "A\u03b2 removal and improved cognitive function in animal models of AD. Clinical trials on various drugs, including AN1792, bapineuzumab, and solanezumab,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23568994", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 112, 
            "offsetInEndSection": 156, 
            "text": "solanezumab, an anti-\u03b2-amyloid (A\u03b2) antibody", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22672770", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 997, 
            "offsetInEndSection": 1081, 
            "text": "Anti-A\u03b2 monoclonal antibodies (bapineuzumab and solanezumab) are now being developed", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1424, 
            "offsetInEndSection": 1571, 
            "text": "Solanezumab, a humanized anti-A\u03b2 monoclonal antibody directed against the midregion of the A\u03b2 peptide, was shown to neutralize soluble A\u03b2 species. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 192, 
            "text": "Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the central region of \u03b2-amyloid, a peptide believed to play a key role in the pathogenesis of Alzheimer's disease (AD).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 176, 
            "text": "Solanezumab is a humanized anti-amyloid \u03b2 monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134132", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 358, 
            "offsetInEndSection": 567, 
            "text": "This situation was encountered in the development of LY2062430, a therapeutic mid-domain monoclonal anti-amyloid beta peptide (A\u03b2) antibody undergoing clinical trials for the treatment of Alzheimer's disease. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21868184", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 125, 
            "offsetInEndSection": 250, 
            "text": "Solanezumab is a monoclonal antibody that binds to \u03b2-amyloid (A\u03b2), a protein that plays a key role in the pathogenesis of AD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504387", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 865, 
            "offsetInEndSection": 912, 
            "text": "Solanezumab can neutralize soluble A\u03b2 peptides,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504387", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 139, 
            "offsetInEndSection": 260, 
            "text": "LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20375655", 
            "endSection": "abstract"
        }
    ]
}